Acetyl Hexapeptide-30

Mechanism of action

Proposed as a competitive antagonist of agrin at its binding site on muscle-specific kinase (MuSK), a transmembrane receptor tyrosine kinase on the post-synaptic membrane of the neuromuscular junction. In normal physiology, motor-neuron-secreted agrin binds MuSK via the LRP4 co-receptor, triggering MuSK autophosphorylation and downstream clustering of acetylcholine receptors at the post-synaptic membrane. Blocking this interaction is proposed to reduce post-synaptic responsiveness to acetylcholine and thereby reduce expression-muscle contractions. This mechanism sits alongside — and is marketed as complementary to — the pre-synaptic SNAP-25 inhibition of Argireline-class peptides and the nAChR antagonism of Vialox. Independent mechanistic replication outside Lipotec is minimal.

Primary uses

• Topical cosmetic anti-aging formulations (expression-line reduction — post-synaptic mechanism)

Typical dosing

Regulatory status

Cosmetic ingredient; not a drug. Current INCI name: Acetyl Hexapeptide-30 (formerly Acetyl Hexapeptide-25).

Status as of this entry's last review, October 4, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.

What we checked

Acetyl hexapeptide-30 (sold as Inyline) has no paper indexed on PubMed under its INCI or trade name, and its sequence is not public. This section records what can be checked.

Identity, computed

Its maker has not disclosed the sequence, so no formula or mass can be computed. The INCI name says only that it is an acetylated six-residue peptide; the entry previously recorded a former INCI name, acetyl hexapeptide-25.

Regulatory status, read October 5, 2026

Drugs@FDA: 0 records for “hexapeptide-30”. EMA medicines list: 0 records for “hexapeptide-30”. Run for semaglutide, the same queries return 6 and 5 records (and the registry search 84 trials), so a zero here is an absence, not a broken search. Not named on the WADA 2026 and 2027 Prohibited Lists. As a substance with no current approval for human therapeutic use, it falls under section S0 (non-approved substances), which is prohibited at all times; the lists were read on September 27, 2026.

What the maker or sellers claim

Claim, from its supplier: Inyline relaxes expression lines by interfering with the agrin-MuSK signal that clusters acetylcholine receptors on muscle, a post-synaptic step rather than Argireline's pre-synaptic one. Lipotec (now part of Lubrizol) supplies this ingredient to cosmetic brands; its technical data sheet is not a peer-reviewed source, so its figures are not repeated here.

About the target, not this peptide

Agrin is a protein nerve endings release to cluster acetylcholine receptors at the muscle junction; a 2008 study in Cell showed it acts through the receptor Lrp4, which forms a complex with the kinase MuSK (Kim et al., 2008). That paper is about the biology of the junction and does not test any cosmetic peptide. Whether a topical peptide reaches the junction at all is the same open question raised for Argireline, whose penetration studies find almost none reaching the dermis.

What we looked for and did not find

No peer-reviewed study of this ingredient in cells, animals or people, no published sequence, no registry record. As a cosmetic ingredient it needs no FDA approval in the US; cosmetics are not reviewed for effectiveness before sale.

References

1. [manufacturer] Lipotec / Lubrizol. "Inyline® peptide solution (Acetyl Hexapeptide-30) technical data sheet." Lipotec S.A.U., Gavà, Barcelona.
2. [review] Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. "Cosmeceutical peptides in the framework of sustainable wellness economy." Front Chem, 2020;8:572923. PMID: 33195061.
3. [pubmed] Kim N, Stiegler AL, Cameron TO, et al. "Lrp4 is a receptor for Agrin and forms a complex with MuSK." Cell, 2008;135(2):334-342 (agrin/LRP4/MuSK mechanism). PMID: 18848351.

Related peptides

Guides & tools